PI3K/AKT Simulation Sprint: Optimizing Pathway-Targeted Therapy in HR+ Metastatic Breast Cancer

This activity was originally presented at the 2026 Breast Cancer Day of Education and includes a Pocket Pharmacist.

In collaboration with HOPA, COA, & Oncology State Societies.

Program Description

The PI3K/AKT/mTOR pathway is a central driver of endocrine resistance in hormone receptor–positive (HR+) metastatic breast cancer (mBC). As endocrine resistance remains a significant clinical challenge driven in part by alterations in the PI3K/AKT/mTOR signaling pathway, targeted therapeutics have become a critical component of care. This session examines aberrant signaling through this pathway that enables ligand-independent estrogen receptor activation, necessitating the strategic use of targeted inhibitors to restore endocrine sensitivity. A major focus will be the application of PI3K/AKT inhibitors in frontline, high-risk endocrine-resistant mBC, post-CDK4/6 inhibitor treatment sequencing, and the mechanistic advantages of investigational pan-pathway and dual inhibitors. Through interactive audience response segments, speakers will guide participants through case-based clinical scenarios, highlighting key factors that inform real-world selection including eligibility criteria, high-risk status, biomarker and mutation testing, treatment access and prior authorizations, expected toxicities, and adherence concerns.

Target audience: Oncology pharmacists
Type of activity: Application
Release date: July 30, 2026
Expiration date: July 30, 2027
Learner level: Intermediate, Advanced
Time to complete activity: 1.25 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Identify patients who are appropriate candidates for PI3K or AKT inhibitor–based therapy in frontline and relapsed hormone receptor–positive/HER2-negative (HR+/HER2−) metastatic breast cancer, incorporating biomarker status and clinical features
• Analyze how key PI3K and AKT inhibitor trial data inform real-world treatment selection and sequencing decisions in HR+/HER2− metastatic breast cancer
• Determine proactive monitoring and management strategies for endocrine toxicities associated with PI3K and AKT inhibitors to support treatment adherence and continuity of care

Accreditation

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.25 contact hours (0.125 CEU) under the ACPE universal activity number 0290-0000-26-246-H05-P. The activity is available for CE credit through July 30, 2027.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Faculty

Allison Reed, PharmD, BCPS, BCOP, has the following relevant financial relationships with ineligible companies to disclose:

Consultant: National Comprehensive Cancer Network

The following contributors have no relevant financial relationships with ineligible companies to disclose:

Jordan Hill, PharmD, BCOP

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Rose Buszka, PharmD, BCPS, CHCP; Kylie Ferrentino; and Brianna Winters.

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

Continuing professional education activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved by the labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms